Back to News
Market Impact: 0.48
US FDA approves Lilly's once-weekly insulin injection for type 2 diabetes
Source: reuters.com
Healthcare & BiotechProduct LaunchesRegulation & Legislation
The FDA approved Eli Lilly's once-weekly basal insulin, Onswik, for adults with type 2 diabetes. The approval provides an alternative to daily long-acting insulin injections and expands Lilly's diabetes-treatment portfolio, with potential benefits for patient convenience and treatment adherence.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
LLY0.82
More News
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Hims & Hers earnings up next: Can GLP-1 boom drive profit?
- Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss
- Novo Nordisk: Q3 Earnings Bust The Cannibalization Myth
- 3 Large-Cap Stocks to Watch as Drug & Biotech Sector Rebounds in 2026
- Jim Cramer's top 10 things to watch in the stock market Monday